Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating several treatments for adults with kidney failure who have recently been diagnosed with calciphylaxis, a rare disease affecting about 1 to 2 people in 10,000. This phase 3 global platform trial aims to provide high-quality evidence on the effects of different therapies across various care areas. The study uses an adaptive design to add or remove treatment options based on ongoing results, improving how patients with this condition are treated. The trial begins with two main treatment areas the Dialysis Membrane Domain and the Pharmacotherapy Domain. In the Pharmacotherapy Domain, participants receive either Vitamin K1 capsules, Magnesium Citrate tablets, Sodium Thiosulfate injections, or placebos, with dosing schedules matched to their dialysis sessions. The Dialysis Membrane Domain compares two types of dialysis filters, high flux and medium cut-off dialysers, in an open-label design. Treatments are given according to these schedules, and new interventions may be added as the trial progresses. Participants will be monitored and assessed using the BEAT-Calci Wound Assessment Scale over 12 weeks as the primary outcome, with additional evaluations up to 26 weeks and beyond. Assessments include wound measurements, pain levels, analgesic use, quality of life, infection rates, hospital days, mortality, kidney transplantation status, and calciphylaxis recurrence. The study uses a Bayesian adaptive approach to adjust sample size and study arms based on collected data, continuing until clear results on treatment effects are reached.
Actively Recruiting
Researchers are evaluating whether metformin, a medication commonly used for diabetes, can be repurposed to slow kidney function decline in adults diagnosed with early-stage Autosomal Dominant Polycystic Kidney Disease ADPKD. ADPKD causes cyst growth in kidneys leading to pain, high blood pressure, chronic kidney disease, and reduced quality of life. This global Phase III randomized controlled trial aims to find effective, affordable treatments to reduce illness impact and improve life quality for ADPKD patients. Participants are randomly assigned to receive either extended-release metformin Metformin XR or a placebo, alongside standard care, for 104 weeks. The metformin dose ranges from 500 to 2000 mg daily based on individual tolerance and kidney function. The study includes a control group receiving identical placebo tablets for comparison. This design allows assessment of metformins effect on slowing disease progression. During the study, participants undergo regular monitoring including kidney function tests, assessment of kidney disease progression, quality of life questionnaires, and tracking of side effects and healthcare use over 24 months. The primary outcome is the change in estimated glomerular filtration rate eGFR. Secondary outcomes include kidney failure, mortality, medication dosing changes, and symptoms related to ADPKD. Safety and effectiveness are carefully followed throughout the trial period, which may last until 2030.
Actively Recruiting
Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options. Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study. During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.
Actively Recruiting
Researchers are conducting an international, multi-center Phase III trial called CAPTIVATE to study treatments for chronic kidney disease CKD, which affects over 800 million people worldwide and can lead to kidney failure and other serious health problems. The trial aims to identify the best single or combined treatments that can slow CKD progression and reduce the number of people developing kidney failure. CAPTIVATE uses an adaptive platform design allowing multiple therapies to be tested efficiently within a common framework, with the flexibility to add or remove treatments over time. Participants may join one or more treatment domains and receive each study treatment for 2 years. Treatments under study include finerenone tablets taken once daily and semaglutide injections given once weekly, along with their matching placebos. Participants will attend scheduled study visits at approximately 1 month, 3 months, 6 months, 12 months, 18 months, and 2 years after starting treatment, with a final visit one month after treatment ends. The trial is ongoing and will continue recruiting for several years. During the study, participants undergo blood and urine tests, safety checks, and assessments of treatment adherence at regular visits. The research team collects information on overall health status every 5 years. The primary outcomes focus on treatment effects measured from randomization through week 108, with various secondary outcomes tracked throughout the study. Safety is monitored continuously, and participants remain under their usual care alongside the trial procedures.
Actively Recruiting
This research aims to find out whether an early three-day oral steroid treatment called dexamethasone can improve both physical and mental recovery in children with Sydenhams chorea. Sydenhams chorea is a movement disorder caused by brain inflammation after an abnormal immune response to certain bacterial infections, affecting childrens movements, mood, and concentration. The condition commonly affects children with acute rheumatic fever, and recovery can take months. The study is a phase 3, randomized, double-blinded, placebo-controlled trial involving children in New Zealand and Australia. Participants will be randomly assigned to receive either oral dexamethasone or a placebo for three days. The dexamethasone dose is 20 mg per square meter of body surface per day, divided into three doses, with a maximum of 24 mg per day. The placebo group will take matching capsules on the same schedule. This short course treatment is being tested to see if it reduces the severity of Sydenhams chorea and its psychiatric symptoms. Children in the study will be monitored through scheduled visits on days three, seven, one month, three months, and twelve months. Researchers will assess chorea severity, relapse rates, psychiatric symptoms, hospital stay length, and treatment failure. Safety will be checked for any side effects possibly related to dexamethasone. The trial plans to recruit 80 participants, and overall involvement may last up to 12 months to track recovery and treatment effects comprehensively.
Actively Recruiting
Researchers are evaluating the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instruments in patients undergoing primary or revision shoulder arthroplasty. The study aims to confirm implant survival over 10 years, monitor adverse events, and assess improvements in shoulder function, pain, quality of life, and radiographic outcomes using standard scoring systems and imaging. Participants will receive the Zimmer Biomet Total Shoulder Arthroplasty System, including devices like the Alliance Glenoid and Identity Stem, designed for various types of shoulder replacements. The study will follow patients for 10 years to track implant survival and safety, with a 2-year evaluation focusing on clinical performance and radiographic measures. During the study, patients will undergo assessments of implant survival using the Kaplan Meier method, adverse event monitoring, and evaluations of shoulder function with the American Shoulder and Elbow Surgeons ASES score, quality of life questionnaires, and detailed radiographic imaging. Follow-up visits at 2 years and up to 10 years will help researchers understand the long-term results of the shoulder arthroplasty system.